Wädenswil ZH – Creoptix has raised 8 million Swiss francs in a financing round. The start-up from the Greater Zurich Area develops analytical laboratory devices used in Life Sciences research and the pharmaceutical industry.

Creoptix has successfully raised 8 million francs in a Series C financing round. The process was led by Swisscanto Invest by Zurich Cantonal Bank, as detailed in a press release. The US technology firm Waters Corporation was also involved in addition to existing private investors. Following the closing of its most recent financing round, Creoptix has now raised a total of 15 million francs from investors since 2013.

Creoptix develops and operates analytical devices for laboratory analysis in biochemical and pharmaceutical laboratories. The devices allow the interactions between even the most minute molecules to be investigated in real time, facilitating new approaches in drug development, among other benefits. The company’s lead product is Creoptix WAVE, a high-tech device used to analyze the interactions between molecules, for example the process of drugs binding to their target.

With this fresh capital, Creoptix intends to drive forward its expansion within Europe and in the USA, as explained by Matyas Vegh, CEO of Creoptix.

Creoptix was founded in 2009 and is headquartered in Wädenswil ZH. The company also has offices in the USA.

Weitere News

Meet with an expansion expert

Our services are free of charge and include:

  • Introduction to key contacts in industry, academia, and government
  • Advice on regulatory framework, taxes, labor, market, and setting up a company
  • Custom-made fact-finding visits, including office and co-working space